Kornimate/medical-research-clean huggingface dataset:
using models' facial expressions to enhance healthy eating behaviour in children

Conditions: Eating Behavior

Summary: this study examined the effect of adults' facial expressions (fes) whilst eating raw broccoli on children's acceptance and intake of a typically less preferred vegetable. investigating others' fes in isolation (e.g., without statements about food tastiness) will improve understanding of the role of fes in modelling of eating and contribute to developing strategies to help children learn pleasure from nutritious foods. based on previous literature, it was hypothesised that children's acceptance (willingness to try, and frequency of taste exposures) and intake of raw broccoli would be higher after exposure to models eating raw broccoli with positive fes, compared to models consuming raw broccoli with neutral fes, or a non-food control video.

research has shown that seeing positive facial expressions towards food are effective for increasing children's desire to eat foods rated as disliked. however, the effect of adults' positive facial expressions whilst eating a raw vegetable on children's acceptance and consumption of nutritious foods that are less preferred (e.g., vegetables) remains to be established. this study examined the effect of unfamiliar adult models' facial expressions eating raw broccoli on children's acceptance and consumption of raw broccoli. children aged 4-6-year-olds were randomised to watch a video of unfamiliar adult models eating raw broccoli with a positive or neutral facial expression, or a non-food control video. children's acceptance (willingness to try and frequency of taste exposures) and consumption of raw broccoli was assessed. data about parent and child characteristics was provided by parents.

Eligibility criteria:
inclusion criteria: * child must be aged 4-6-years old. parent and child must be living in the uk. exclusion criteria: * children with food allergies, food intolerances, or medical conditions that affect eating behaviour were not eligible to take part.

Keywords: children
microarray analysis of microrna expression profiles in cutaneous squamous cell carcinoma

Conditions: Cutaneous Squamous Cell Carcinoma

Summary: micrornas (mirnas) are a novel class of short rnas which have shown to be dysregulated in a variety of cancers. data of mirna expression in cutaneous squamous cell carcinoma (cscc) is very limited and microarray based genome wide mirna expression profiles of cscc have not been investigated so far.

patients with cutaneous scc were enrolled in the present study. tumor biopsies were taken from the center of the tumor. adjacent healthy skin was biopsied as a control (intraindividual control). mirna expression profiles of specimen were detected by microarray mirna expression profiling. microarray results were confirmed by taqman real-time quantitative polymerase chain reaction (rt-pcr).

Eligibility criteria:
inclusion criteria: * cutaneous squamous cell carcinoma exclusion criteria: * other skin cancer than cutaneous squamous cell carcinoma
open label extension for patients coming from the dosing flexibility study in patients with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (mtx).

patients having completed the week 34 assessment in the c87077 (nct00580840) study or having met the pre-defined criteria for flare (defined as patients that have randomized at week 18 and experienced at 2 consecutive visits between week 18 and week 34 inclusive an equal to baseline (w0) or worst swollen and tender joints counts), will be given the option to enroll in c87084 and receive certolizumab pegol \[400 mg at entry, week 2, and week 4 followed by 200 mg every two weeks (q2w)\] in combination with mtx until the drug is commercially available for the indication of rheumatoid arthritis (ra) in the patient's country or region or until further notice from ucb. all patients will continue their mtx treatment at the same stable dose as during the c87077 (nct00580840) study, unless there is a need to reduce the dose for reasons for toxicity.

Eligibility criteria:
inclusion criteria: * patients must be able to understand the written informed consent form (icf) * patients must have achieved an acr20 (american college of rheumatology) response at week 16 and completed the entire c87077 (nct00580840) study or patients having been randomized at week 18 and having met the pre-defined criteria for flare * patients must have complied with the protocol requirements during their participation in c87077 (nct00580840) * female patients of childbearing potential must have a negative urine pregnancy test at entry and must continue to have negative urine pregnancy tests throughout their study participation * patients must be willing to comply with protocol exclusion criteria: * patients must not have a diagnosis of any other inflammatory arthritis * patients must not have a secondary, non-inflammatory type of arthritis that in the investigator's opinion is symptomatic enough to interfere with the evaluation of the study drug on the patient's primary diagnosis of rheumatoid arthritis (ra) * patients must not have a history of an infected joint prosthesis with that prosthesis still in situ * patients who do not meet the medical history exclusion criteria, as defined per protocol. examples of exclusionary criteria (not all-inclusive): pregnancy, chronic infection, active tuberculosis (tb), high risk of infection, lymphproliferative disorder, acute or chronic viral hepatitis b or c, known human immunodeficiency virus (hiv), malignancy or history of malignancy, history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease

Keywords: rheumatoid arthritis joint disease arthritis certolizumab pegol cimzia
awareness, care, and treatment in obesity management of patients with hemophilia (action) to inform hemophilia obesity patient empowerment (hope)

Conditions: Haemophilia A, Haemophilia B, Obesity

Summary: an online web-based cross-sectional survey in which participants will complete a distinct questionnaire for patients with hemophilia and obesity (pwho) and/or their carers/spouses/partners, or a distinct questionnaire for healthcare professionals. each questionnaire consists of more than 100 items including pre-coded (multiple choice) closed-ended questions, yes/no questions and rating scales. it is estimated that this one-off survey will take approximately 45-60 minutes to complete. as a cross-sectional study, there will be no treatment of patients.


Eligibility criteria:
inclusion criteria: * meeting one of the following criteria: a) adults (any gender) aged equal to or more than 18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight, - or - caregivers of children (any gender) currently aged less than18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight, - or - spouses or partners of adults (any gender) aged equal to or more than 18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight - or - healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight. * participants must have access to the internet, either at home or at a location convenient to them * provision of informed consent before the start of any survey-related activities. exclusion criteria: * inability to understand and comply with written instructions in english * previous completion of this study with receipt of compensation * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
pulmonary hypertension, quality of life and psychosocial factors

Conditions: Pulmonary Hypertension

Summary: the investigators aim to : * describe and analyse psychological characteristics, cognitive factors and representations in patients with pulmonary hypertension, a rare disease. * assess the psychological characteristics impact on quality of life, check the association between disease and qol evolution, and the variability of qol parameters over severity class changes and follow-up

pah is a rare, and severe disease, potentially mortal, affecting preferentially young subjects. the knowledge and the international literature, as regards the quality of life, the expectations, the needs and the psychosocial characteristics of patients with pah, are non-existent. but it is known that the persons affected by rare diseases are more vulnerable, on the psychological, social, economic and cultural planin all the stages of the treatment, patients with pah are confronted with heavy psychosocial situations, in a context of vital risk, with exceptional medicinal treatments (intravenous administration at home). * qol might be differently affected by these changes according to situational and dispositional psychological dimensions. * the predictive role of these characteristics on the current and later quality of life, as well as the impact of diverse cognitive mediators and strategies to cope with the disease, should be investigated.the respiratory diseases department of the montpellier hospital is regional competence center for pah in languedoc-roussillon, under the aegis of the national reference center (the respiratory diseases department of antoine béclère hospital, le petit-clamart).

Eligibility criteria:
inclusion criteria: * patients with pah * patients stable since 3 months * patients with a severity of class i to iv * patients aged between 18 and 80 years * patients no psychological follow-up at the competence center. exclusion criteria: * patients unable to give his accordance * patients unable to understand the aim of the study * patients with recents psychiatrics disorders * patients with problems of understanding the tests of the study * drug users or drinkers * pregnant or women without efficacy contraception * patient without freedom by administration decision * patient in exclusion period * patient without french insurance * adult protected by the law

Keywords: pulmonary hypertension quality of life coping depression anxiety social support control beliefs
morphine gel for bedsores

Conditions: Decubitus Ulcer

Summary: this study tests the effectiveness of a morphine-containing gel for reducing pain caused by pressure ulcers, also known as bedsores or pressure sores. we will apply the gel containing morphine, or the gel alone, directly onto painful pressure ulcers and compare the results.

in this study, we will apply a morphine-containing gel (or placebo) directly onto painful pressure ulcers. we will take participants off of any opioid-containing medications upon entry into the study. this allows us to measure any morphine that may enter into the bloodstream from the topically applied gel. the purpose of this study is to examine the efficacy of the gel for pressure ulcer analgesia, as well as the systemic absorption of morphine from the topically applied gel. we will document the amount of pain medications taken by participants to determine whether the gel decreases the need for these drugs.

Eligibility criteria:
inclusion criteria: * presence of a stage ii pressure ulcer. * pressure ulcer must be painful. * primary care physician must approve participation. * thinking ability must be clear and intact. * willing to change pain medication to oxycodone. exclusion criteria: * allergy to morphine, oxycodone or intrasite gel. * use of codeine- or morphine-containing medications. * use of pain medications for anything other than the pressure ulcer.

Keywords: analgesia bedsore morphine gel pressure ulcer pain ulcer
evaluation of a training in the walking with exosquelette

Conditions: Gait; Stroke; Robotic Rehabilitation

Summary: stroke patients in the investigators rehabilitation unit follow gait trainings with robotic-assistive devices such as lokomat. patients able to walk alone are also assessed with 3d gait analysis. the objective of this study is to assess the effects of gait training in lokomat on biomecanic gait parameters in stroke patients.


Eligibility criteria:
inclusion criteria: * single stroke * able to walk alone * \> 18years exclusion criteria: * cognitive impairments disturbing understanding * uncontrolled medical disorder associated
study of dapagliflozin on mitochondrial dysfunction and impaired insulin signaling/action

Conditions: Insulin Sensitivity; Multiple Mitochondrial Dysfunctions Syndrome

Summary: the purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (t2dm) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. dapagliflozin is a potent, highly specific inhibitor of renal glucose transport \[sglt2\].

"glucotoxicity" has been implicated as a cause of insulin resistance and impaired beta cell function in t2dm. abundant support for the glucotoxicity hypothesis has been provided by in vivo and in vitro studies in animals, but a rigorous test of this hypothesis in man is lacking. the investigators propose to test the glucotoxicity hypothesis by chronically reducing the plasma glucose in type 2 diabetic subjects (t2dm) with an inhibitor of renal glucose transport, dapaglifozin, and examining the effect of restoration of normoglycemia on mitochondrial function and insulin signaling/sensitivity. lastly, the investigators will test the "glucolipotoxicity" hypothesis, which states that the toxic effects of elevated plasma ffa on insulin sensitive tissues (i.e., muscle) are magnified in the presence of concurrent hyperglycemia. thus, high glucose levels increase malonyl coa, which inhibits cpt i, leading to accumulation of facoa/dag, which impair mitochondrial function and inhibit insulin action.

Eligibility criteria:
inclusion criteria: * t2dm * drug naive or on oral therapy exclusion criteria: * insulin treatment * major organ disease

Keywords: insulin sensitivity mitochondrial function glucose toxicity glucosuria
a pilot study on the prevention of the vascular risk related to atrial fibrillation after intracranial hemorrhage by closing the left auricle

Conditions: Atrial Fibrillation; Intracranial Hemorrhages

Summary: atrial fibrillation (af) is a frequent heart rhythm disorder, responsible for the formation of cardiac thrombi, which can embolize in the systemic circulation, responsible for strokes (cerebrovascular accidents). af increases the risk of stroke and stroke-related disability. preventing the thromboembolic risk associated with fmd is therefore a public health issue. the reference treatment is oral anticoagulation but this treatment is contraindicated in patients with a history of intracranial hemorrhage. the percutaneous closure of the auricle is a recent technique which makes it possible to exclude this appendix from the left atrium where the majority of thrombi are formed in the framework of the af. comparative studies have shown the effectiveness of this technique, appearing to be similar to that of anticoagulation. however, in view of the per-procedural risk, the indication of closure was retained by the health authorities only in the event of a contraindication to oral anticoagulants in patients with non-valvular af with a high thromboembolic risk. patients with a history of intracranial hemorrhage are therefore candidates for this technique, but there are few studies where these patients were included. the risk-benefit must be demonstrated over the long term, in terms of ischemic, hemorrhagic recurrence and becoming functional and cognitive.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * affiliation to a social security scheme * non-valvular, paroxysmal, persistent or permanent atrial fibrillation * cha2ds2-vasc greater than or equal to 2 * history of intracranial haemorrhage: intra-parenchymal hematoma, subacute or chronic subcutaneous hematoma and * patients having benefited from the percutaneous closure of the auricle at the university hospital of amiens * either patient admitted to the chu of amiens in neurology, neurosurgery or geriatrics for intracranial haemorrhage, who received standard medical treatment for the comparison group. exclusion criteria: * chads2vasc2 less than 2 * extradural hematoma * arachnoidal haemorrhage by rupture of aneurysm * haemorrhagic transformation of ischemic stroke * other indication of anticoagulation than fa * modified rankin scale greater than 4 following intracranial hemorrhage. * early death, in the month following the onset of intracranial hemorrhage.
improving diagnostic safety through steatosis identification, risk stratification, and referral in the ed

Conditions: Non-Alcoholic Fatty Liver Disease; Steatosis of Liver

Summary: hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. the investigators developed a clinical decision support system using machine learning and natural language processing that will prompt reporting to patients and provide ed clinicians risk stratified follow-up care recommendations. data on both the implementation and effectiveness of our intervention resulting from this trial will inform future use with a goal of ultimately improving diagnostic safety and outcomes for patients with hepatic steatosis.

metabolic associated steatotic liver disease is a public health crisis affecting one third of the us adult population. steatotic liver disease is an obesity related disease with serious health and quality of life consequences. hepatic steatosis is reported on \~10% of written radiology reports. unfortunately, lack of awareness often leads to hepatic steatosis being overlooked by providers and unreported to patients leading to delays in diagnosis and referral to specialty care. this project, improving diagnostic safety through steatosis identification, risk stratification, and referral pathway in the ed (stirred), proposes to improve diagnostic safety by ensuring that patients receive timely notification of the new finding and referral to follow up care. the stirred cdss intervention employs natural language processing and machine learning to identify hepatic steatosis in written emergency department (ed) radiology reports and combine it with common clinical data and co-morbidities in the electronic health record to create an individualized risk profile and follow up recommendations for patients with suspected metabolic associated steatotic liver disease. this recommendation is communicated to the ed clinician during the ed discharge process via an ourpractice advisory (opa) and triggering outpatient referral for follow-up care stratified by risk level. this trial will evaluate stirred across a large health system using a type 2 implementation-effectiveness stepped wedge cluster randomized trial across 11 emergency departments in a single health system. effectiveness of providing risk-based care linkage and implementation outcomes will be evaluated.

Eligibility criteria:
inclusion criteria: * imaging finding of hepatic steatosis on ed imaging study * discharged from the ed to home * first northwestern medicine ed visit in the study period with a hepatic steatosis finding exclusion criteria: * admitted to the hospital * age \< 18 * pre-existing liver disease diagnosis (liver cancer, hcv, hbv, cirrhosis, nafld/masld/nash/mash, alcohol liver disease, psc, pbc and autoimmune hepatitis) * multiple incidental findings on ed imaging study

Keywords: metabolic associated steatotic liver disease incidental radiology finding emergency medicine
magnetic resonance imaging (mri) in amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: this is a pilot study to identify the degree of grey and white matter involvement in patients with amyotrophic lateral sclerosis (als) utilizing non-invasive techniques. the imaging to be utilized will be the 7 tesla (7t) magnetic resonance imaging (mri) of the brain. these results will be correlated to the als functional rating scale - revised (alsfrs-r) score to assess if any changes in mri can be predictive in the disability of the als patients at baseline and at 6 month intervals. the participants will be asked to return every 6 months for a neurological examination, alsfrs-r assessment, measurement of the vital capacity and mri as outlined above to monitor progression of the disease.


Eligibility criteria:
inclusion criteria: * males and females who are 18 - 80 years old. * the participants will meet the standard diagnostic criteria for possible or probable als (based on el escorial criteria). they will have been diagnosed by a johns hopkins neurologist. * healthy controls will be recruited by their interest in assisting the als population. exclusion criteria: * forced vital capacity less than 60 % of predicted value. * documented orthopnea on alsfrs-r or otherwise unable to lie flat in an mri scanner for the duration of the study. * presence of pacemakers, aneurysm clips, shrapnel or otherwise disallowed implanted metallic devices for obtaining an mri scan. * pregnant or lactating females * glomerular filtration rate (gfr) less than 60 * history of: encephalitis, extensive white matter disease, intracranial hemorrhage, cerebral palsy, allergy to dye and/or iv drug abuse.
outcomes of pfa vs. rfa for patients with psvt: a retrospective and propensity score matching study

Conditions: Paroxysmal Supraventricular Tachycardia; Catheter Ablation

Summary: the goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (pfa) vs. radiofrequency ablation (rfa) for the patients with paroxysmal supraventricular tachycardia (psvt). the main question to answer is: does the pfa was more effecient and safer that rfa for treatment of psvt during procedure and after 1-year follow-up? researchers will compare the acute and long-term efficiency and safety between pfa and rfa. 1. recieved pfa or rfa 1 year ago 2. finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings 3. patients recieved pfa and pfa under propensity matched comparison according to differen variety of psvt

the goal of this retrospective study is to compare the long-term follow-up outcomes of pfa vs. rfa for the patients with psvt. the main question to answer is: does the pfa was more effecient and safer that rfa for treatment of psvt during procedure and after 1-year follow-up? researchers will compare the acute and long-term efficiency and safety between pfa and rfa.

Eligibility criteria:
inclusion criteria: 1. patients with symptomatic psvt including: atrioventricular nodal re-entrant tachycardia (avnrt), atrioventricular re-entrant tachycardia (avrt); 2. age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction; 3. willing to receive the examinations and testings during one year follow-up required by the protocol; 4. voluntary signed informed consent. exclusion criteria: 1. organic heart disease; 2. history of cardiac surgery; 3. previous failed ablation of psvt; 4. presence of any implants, such as a permanent pacemaker; 5. patients with invasive systemic infections or advanced malignant tumors; 6. contraindications for septal puncture or retrograde transaortic access surgery; 7. any condition that makes the use of heparin or aspirin inappropriate; 8. pregnant or lactating women; 9. inability to fully comply with the study procedures and follow-ups or to provide their own informed consent; 10. coexistence with other arrhythmias, such as atrial fibrillation.

Keywords: paroxysmal supraventricular tachycardia pulsed field ablation radiofrequency ablation